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PURPOSE. To isolate, culture, and characterize primary human choroidal endothelial cells, and
to assess their responsiveness to corticosteroids, in order to enable knowledge gain on the
pathogenesis of central serous chorioretinopathy.
METHODS. Choroidal endothelial cells were isolated from cadaveric human donors. Magnetic-
activated cell sorting with anti-human CD31 was performed for choroidal endothelial cell
isolation. Primary cultures of purified choroidal endothelial cells were treated with several
regimens of corticosteroids and analyzed for effects on primary corticosteroid responsive
genes.
RESULTS. Isolated choroidal endothelial cell cultures had a cobblestone appearance in
monolayer cultures and stained positive for vascular endothelial cadherin. Moreover, on a 3D-
Matrigel matrix, these cells formed capillary-like structures, characteristic of in vitro
endothelial cells. Primary cultures of purified choroidal endothelial cells treated with several
regimens of corticosteroids demonstrated significant transcriptional upregulation of primary
corticosteroid responsive genes (FKBP5, PER1, GILZ, and SGK1). Further pharmacologic
analysis using specific agonists (dexamethasone, aldosterone) and antagonists (mifepristone,
spironolactone) for either the glucocorticoid receptor or the mineralocorticoid receptor
showed that this response was exclusively mediated by the glucocorticoid receptor in our
model.
CONCLUSIONS. With this optimized choroidal endothelial cell isolation and culturing protocol,
we have established an in vitro model that appears very suitable for research on both central
serous chorioretinopathy and other diseases in which corticosteroids and choroidal
endothelial cells are involved. Our model proves to be suitable for studying effects mediated
through the glucocorticoid receptor. The role of mineralocorticoid receptor-mediated effects
needs further research, both in vivo and in cell model development.
Keywords: central serous chorioretinopathy, human choroidal endothelial cells, primary
endothelial cell isolation, glucocorticoid receptor, mineralocorticoid receptor
Central serous chorioretinopathy (CSC), similar to otherocular diseases, finds its origin in the choroid.1 The
neuroretinal detachment that characterizes CSC patients
presumably occurs secondary to choroidal congestion, thick-
ening, and hyperpermeability. This leads to dysfunction of the
retinal pigment epithelium (RPE), which can subsequently
cause leakage of serous fluid to under the neuroretina.2–4 The
exact cause of CSC is unknown, but many risk factors have
been addressed.2,3,5,6 Corticosteroid use is the most well-
established exogenous risk factor in CSC, with reported odds
ratios of up to 37.7 Remarkably, the established correlation
between exogenous steroid use and the occurrence of CSC is
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independent of duration and route of administration and
prescribed dosage.8,9 Because corticosteroids bind to both the
glucocorticoid receptor (GR) and the mineralocorticoid
receptor (MR), it has been hypothesized that both are involved
in the pathogenesis of CSC.5,9–12
Because of the plausible role of the choroidal endothelium
in the pathophysiology of CSC, culturing of human choroidal
endothelial cells (CECs) is of particular interest.13–16 Endothe-
lial cells (ECs) are heterogenic cells that show substantial site-
specific structural and biochemical variation due to their
interaction with their surroundings.17 This cell type is involved
in maintaining the integrity of the blood vessel wall and
controlling the transfer of molecules.18 ECs also interact with
smooth muscles, platelets, and white blood cells through
either paracrine or endocrine actions.19 Ocular ECs have been
found to show significant variation in their function and
response to certain treatments.20 Moreover, gene expression
and cell signaling have been shown to differ significantly
between ECs from different origin.21 Thus, the effect of
corticosteroids on gene expression and signaling pathways in
ECs should be studied preferably on a site- and species-specific
basis. The successful isolation and culture of ECs in general,
and from the choroid in particular, has been reported before by
using various techniques.13–16,22
The primary goal of this study was to develop a culturing
protocol for human primary donor-derived CECs and to assess
the responsiveness of such CECs to corticosteroids, as a basis
to gain knowledge on diseases associated with CEC dysfunc-
tion, such as CSC.
MATERIALS AND METHODS
Human Donors
Eyes from human cadaveric donors (n¼ 8) were obtained from
the Netherlands Brain Bank (Amsterdam, the Netherlands) (n¼
2) or the Department of Anatomy and Embryology of Leiden
University Medical Centre (Leiden, The Netherlands) (n ¼ 6)
and dissected within 24 hours after death. From every donor,
both eyes were used for all experiments, which were
processed and cultured separately. The number of donors
used for each experiment and their age is stated in the caption
of the figures. Donors had no known history of either ocular or
vascular disease. The study was approved by the local medical
ethical committee and followed the Tenets of the Declaration
of Helsinki. Prior written informed consent for organ and tissue
use in research was given by each donor.
Primary CEC Isolation and Culture
A flowchart for the isolation of human primary CECs is depicted
in Figure 1. To isolate primary CECs from human eyes, an
optimized protocol specific for this cell layer was designed
based on the outcome of other studies.14,22 In brief, eyes were
washed in 70% ethanol for 20 seconds and then placed on
Hanks’ balanced salt solution (Gibco Life Technologies, Paisley,
UK) in a petri dish. Extraocular tissue and the anterior segment
structures were removed. The eye was cut into three equal
parts. After removing vitreous body remnants and the neuro-
retina, the peripheral part of the RPE/choroid complex was
removed by cutting along the transition zone because CSC most
often occurs foveally. The RPE/choroid complex was detached
from the sclera, incubated for 1 hour at 378C in 0.05% trypsin-
EDTA (TE), and transferred to cold PBS (B. Braun Medical B.V,
Oss, The Netherlands). The loosened RPE was gently removed
as much as possible with a camel hair brush by using a
dissection microscope (MZ6; Leica Camera, Wetzlar, Germany).
The underlying choroid was washed in PBS at 300g for 3
minutes and digested in 2 ml of 0.2% collagenase type II (C2674;
Sigma-Aldrich, Steinheim, Germany) on a 378C shaking water
bath. Digestion was stopped by adding 10 ml of Dulbecco’s
modified Eagle’s medium (DMEM) without pyruvate (Gibco Life
Technologies) supplemented with 10% heat-inactivated fetal calf
serum (FCSi; Sigma-Aldrich). The suspension was filtered
through a 30-lm cell strainer (MACS SmartStrainer; Miltenyi
Biotec B.V., Leiden, The Netherlands), centrifuged at 300g for 5
minutes, and resuspended in EGM-2MV medium (BulletKit CC-
3202 EGM-2MV [including 5% FCS, but without adding
hydrocortisone]; Lonza, Walkersville, MD, USA). Cells were
seeded in 3 wells of a 6-well plate, 1.5 ml of medium per well,
which were coated with 1 ml of 1003 diluted fibronectin
(catalog no. F1141; Sigma-Aldrich) for 30 minutes at room
temperature (RT). Cells were incubated at 378C with 5% CO2.
The medium was changed three times per week, and cell
morphology was regularly checked with a microscope (Axiovert
25 CFL; Carl Zeiss AG, Oberkochen, Germany).
Magnetic-Activated Cell Sorting
After 7 to 10 days, when the primary mixed culture showed
cell islands with EC-like morphology, magnetic-activated cell
sorting (MACS) was used to isolate CECs. For this purpose, the
anti-human CD31 MicroBead Kit and LS columns on a
MidiMACS separator (all from Miltenyi Biotec B.V.) were used
according to the manufacturer’s instructions. A TE concentra-
tion of 0.01% was used, and cells were maintained in DMEMþ
10% FCSi. CECs were resuspended and seeded on fibronectin-
coated 6-well plates in EGM-2MV medium (3 to 5 wells per eye,
1 ml fibronectin dilution per well, 1.5 ml EGM-2MV per well).
Four to 7 days later, MACS was repeated to obtain sufficient
pure CEC cultures, after which cells were seeded on 12-well
plates (12 wells per eye, 0.5 ml fibronectin dilution per well, 1
ml EGM-2MV per well). All treatment experiments were
performed during the second passage (i.e., after two MACS
procedures) at near confluency and TriPure (Roche, Basel,
Switzerland) was added directly afterward for RNA isolation.
Immunocytochemistry
Cells were cultured on chamber slides (Nunc Lab-Tek Chamber
Slide System, C7182; Sigma-Aldrich) fixed with 4% paraformal-
dehyde (Sigma-Aldrich) for 10 minutes and washed in PBS.
Blocking was performed in 1% bovine serum albumin (A7906-
100G; Sigma-Aldrich) and 0.01% Triton X-100 in PBS/tween-20
(PBST; Merck & Co., Kenilworth, NJ, USA) for 30 minutes. The
anti-VE-cadherin antibody (ab33168; Abcam, Cambridge, UK)
was diluted in blocking buffer at 1:350 and left at 48C for
overnight incubation. Samples were washed with PBST for 5
minutes and incubated with Alexa Fluor 647 (A-21244; Thermo
Fisher Scientific, Waltham, MA, USA) diluted 1:250 in blocking
solution for 90 minutes at RT. Finally, samples were washed
with PBST and mounted with ProLong Gold Antifade with 40,6-
diamidino-2-phenylindole (P36931; Thermo Fisher Scientific).
CEC Tube Formation Assay
Capillary-like tube formation is a functional characteristic of
ECs when cultured on a 3D matrix.23 To further assess the
functionality of the isolated CECs, growth factor-reduced
Matrigel (BD Biosciences, San Jose, CA, USA) was placed on
prechilled l-Slide angiogenesis (Ibidi GmbH, Planegg/Mar-
tinsried, Germany), with a final thickness of 0.8 mm. On the
same slide, other wells were coated with fibronectin and the
slide was incubated for 30 minutes at 378C to allow the coating
material to solidify. An equal amount of CECs suspended in
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EGM-2MV growth medium was seeded on either the Matrigel
or fibronectin-coated wells and incubated at 378C. Every 2
hours, CECs on both Matrigel and fibronectin were observed
for cell growth and tube formation with a microscope.
Assessing the Optimal Treatment Regimen of
Cortisol
To determine the most effective regimen of cortisol (H0888;
Sigma-Aldrich) treatment, different treatment schedules were
assessed (either short-time [4 hours], intermittent, or contin-
uous treatment) (Table 1). The EGM-2MV medium contained 5
nM cortisol (originating from the fetal calf serum), resembling
baseline cortisol levels. CECs were treated with either 107 M
cortisol dissolved in ethanol or with vehicle (0.1% ethanol
dissolved in EGM-2MV medium). Medium was changed for all
samples at the four different time points. Every treatment
group of all experiments consisted of a technical triplicate (3
wells of a 12-well plate).
Dose Response Curve
CECs were treated for 4 hours with a serial diluted cortisol
dose starting with the highest dose or with vehicle. The
maximum efficacy (Emax) between genes and half maximal
effective concentration for gene expression response (EC50)
were calculated using GraphPad Prism (version 7; GraphPad
Software Inc., San Diego, CA, USA).
Treatment of CECs With GR and MR Agonists and
Antagonists
The regulation of corticosteroid target genes directly mediated
by the GR was assessed by comparing CECs treated with
FIGURE 1. Flowchart of the isolation of human CECs. First (A), eyes were dissected to separate the choroid from the other layers and to divide the
choroid into central and peripheral parts to be processed separately. The choroidal tissue was then enzymatically digested using trypsin/EDTA (TE).
(B) The remnants of RPE were brushed away (RPE/choroid dissection). Single-cell suspension of the choroid was obtained by collagenase digestion.
Cells were cultured for 4 to 7 days and the MACS was performed after reaching 70% to 80% confluence, after which the same procedure was
performed 4 to 7 days later. (C) Primary cultures of purified CECs were used during the different corticosteroids treatment experiments. Finally,
qPCR was performed to investigate the differential gene expression of the cultured CECs.
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cortisol to those treated with different doses of the GR agonist
dexamethasone (D4902; Sigma-Aldrich). Moreover, the effect
on target gene expression mediated by MR was determined by
comparing treatment with cortisol to treatment with different
doses of the MR agonist aldosterone (A9477; Sigma-Aldrich). In
addition, we evaluated the effect of the GR antagonist
mifepristone (M8046; Sigma-Aldrich) and the MR antagonist
spironolactone (S3378; Sigma-Aldrich) when administered
together with cortisol. An overview of the conducted
experiments is shown in Table 2.
RNA Isolation, cDNA Synthesis, and Quantitative
PCR
RNA isolation was performed using TriPure (Roche) accord-
ing to manufacturer’s instructions. For reverse transcription,
M-MLV reverse transcriptase was used, and quantitative PCR
(qPCR) was performed with SYBR Green master mix,
according to the manufacturer’s instructions (all Promega
Benelux B.V., Leiden, The Netherlands). Gene expression was
normalized to LRP10 and calculated using the 2DCt
method.24 Corticosteroid responsive genes FKBP5, PER1,
GILZ, and SGK1 were selected based on available litera-
ture.25–29 Markers for ECs, including vWF, CDH5, CD31,
CD34, and PLVAP, the latter as a marker for fenestrated
capillaries,30 were used. The expression of VIM was measured
as a marker for fibroblasts to quantify possible contamination
of the EC culture.31 Sequences of primers are shown in
Supplementary Table S1.
Statistical Analysis
SPSS Statistics (version 20.0; IBM Corp., Armonk, NY, USA) was
used to analyze the difference in relative gene expression
between 107 M cortisol and vehicle treatment. The expres-
sions of eight genes were examined for distribution and were
log-transformed to correct for skewness of data. Analysis was
performed using a linear mixed effects model (P ¼ 0.00625,
corrected for multiple testing) on the log-transformed relative
gene expression values per gene. To take into account that
multiple samples and qPCR measurements were collected from
the same donor (i.e., that data from the same donor are
correlated), a random intercept term has been assumed. Only
the treatment effect was investigated. The P values are
reported with the 95% confidence interval of the log-
transformed relative gene expression for both treated and
control samples (Supplementary Table S2).
GraphPad Prism was used for statistical analysis for the
experiments with dexamethasone, aldosterone, and antago-
nists, as well as for the dose response curve. To investigate
TABLE 1. Overview of the Assessed Treatment Schedules
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differences between treatments, the mean difference between
corticosteroid-treated and control samples was estimated using
a 1-way ANOVA with Dunnett correction. For the statistical
analysis of the dose-response curve, a Friedman ANOVA with
Dunn’s multiple comparison test was performed. A Student’s
paired t-test was used to analyze the differences in gene
expression between the cultured CECs and the effluent after
two MACS procedures. Differences were considered significant
when a P value was <0.05. All data (arbitrary units) are
normalized to their respective vehicle.
RESULTS
CEC Culture and Characterization
CECs were characterized by their EC-specific morphology,
island formation (Fig. 2A), and cobblestone appearance (Fig.
2B), which was observed after 4 to 7 days. After two MACS
procedures, CECs showed a convex polygonal monolayer with
less than 5% of other cell populations. CECs showed clear
capillary-like tube formation when cultured on Matrigel after 2
to 4 hours, resembling microvascular structures with a clear
lumen (Figs. 2C, 2D).23 CECs stained positive for the
intercellular junction marker vascular endothelial (VE)-cadher-
in (Fig. 2E), whereas MACS-isolated CD31-negative cells stained
negative (Fig. 2F). Moreover, qPCR analysis of both the CEC
cultures and the MACS effluent, showed high expression of the
CEC-specific markers CD31, CD34, CDH5, vWF, and PLVAP in
the CD31-positive cell population (Fig. 2G). For one donor, all
EC markers were measured and the immunofluorescence
staining was performed; for the other donors, CDH5 expres-
sion was measured as an indicator for purity of the CEC
cultures.
Assessing the Optimal Treatment Regimen of 107
M Cortisol
When treated with cortisol for either 4 hours or according to
the intermittent or continuous regimen, CECs showed an
overall transcriptional upregulation of the investigated target
genes (Fig. 3A). PER1 showed the highest fold change in
expression, whereas FKBP5 and GILZ showed moderate
transcriptional upregulation. SGK1 showed no significant
change in any of the conditions. In general, the effect of
continuous cortisol on gene expression was less than that of
either the 4-hour treatment or intermittent treatment. Inter-
mittent treatment was used for the other experiments, as it
mimics the diurnal rhythm of physiologic cortisol exposure.
We next analyzed in detail the effects of cortisol treatment
on gene expression of primary corticosteroid responsive
genes, the corticosteroid receptor coding genes, and endothe-
lial/fibroblast cell markers in the CECs. GR (NR3C1), MR
(NR3C2), four target genes (FKBP5, PER1, GILZ, and SGK1),
VE-cadherin (CDH5) (EC marker), and vimentin (VIM)
(fibroblast cell marker) were tested in all cortisol and vehicle-
treated samples (Fig. 4). Both NR3C1 and NR3C2 were
expressed in cultured CECs, with cycle threshold values of
24.6 6 0.11 and 26.0 6 0.14, respectively. The treatment of
CECs with 107 M cortisol significantly induced the expression
of FKBP5, PER1, and GILZ (P < 0.0001 for all), whereas
NR3C2 was downregulated in cortisol-treated samples com-
pared with controls (P¼ 0.004). Finally, differences in NR3C1
and SGK1 between treated and control samples were
nonsignificant, which was also the case for CDH5 and VIM
(Supplementary Table S2). To test for possible transient
upregulation of SGK1, a treatment for 45 minutes was also
performed (Supplementary Figure S3E).
To assess whether in vitro culture might diminish MR or
GR expression, mRNA of directly postmortem isolated CECs
and protein of cultured CECs were analyzed. Expression of
the MR appeared to be variable and substantially lower than
the GR and did not differ from the cultured CECs (Supple-
mentary Fig. S4).
Dose-Response Curve
The three target genes FKBP5, PER1, and GILZ were dose-
dependently induced by cortisol (Fig. 3B), with different Emax
and EC50 values. PER1 had the highest Emax, whereas FKBP5
and GILZ had a lower and very similar Emax, respectively.
FKBP5 induction had a low EC50 (6.3 nM), whereas PER1 and
GILZ had higher EC50 values (30 nM and 55 nM, respectively).
SGK1 did not respond to any of the cortisol doses.
Effect on Target Gene Expression of Treatment
With GR and MR Agonists and Antagonists
The administration of the GR agonist dexamethasone resulted
in comparable induction of corticosteroid target genes to that
induced by cortisol, whereas the MR agonist aldosterone did
not induce changes in gene expression in any of the target
genes (Figs. 3C, 5A).
The effects of cortisol were blocked after cotreatment with
the GR antagonist mifepristone but not by the MR antagonist
spironolactone (Fig. 5B). Moreover, the continuous adminis-
tration of spironolactone did not lead to transcriptional
upregulation of the genes of interest, arguing against transcrip-
tional activation via MR caused by cortisol present in the used
serum (Fig. 5C). An overview of (additional/replication)
experiments that concerned treatment with MR agonists and
antagonists is shown in Supplementary Figure S3.
TABLE 2. Summary of All Performed Corticosteroids Treatment Experiments
Experiment Regimen Cortisol Dose Response Curve
MR/GR
Agonist Antagonist
Corticosteroids Cortisol 107 M Cortisol 107 M Cortisol (either 106, 107,
108, or 109) M
Dexamethasone (either
106, 107, or 109) M
and/or aldosterone
(108 or 109) M
Mifepristone 106 M
þ cortisol 107 M
or spironolactone
106 M þ cortisol
107 M
Treatment regimens Vehicle Vehicle Vehicle Vehicle Vehicle
4 hours 4 hours
Intermittent Intermittent Intermittent Intermittent
Continuous
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FIGURE 2. Culture and characterization of human primary CECs. (A–D) Phase contrast photomicrographs of primary CEC cultures. (A) Primary
choroidal mixed cell culture showing an EC-like island after 2 to 3 days of culture on fibronectin in EGM-2MV medium. (B) Primary culture after
MACS showing characteristic EC morphology (cobblestone appearance) with little or no noticed growth of other cell types. (C) Primary CECs
seeded on Matrigel show characteristic formation of capillary-like structures after 2 hours of culture. (D) After 4 hours, CECs cultured on Matrigel
continue to form tubular networks, indicating the ability of these cells to simulate the capillary forming function of ECs. Scale bars are shown in
each panel. (E, F) Immunofluorescence photomicrographs of MACS-isolated CECs (E) and the effluent (F), stained for VE-cadherin (anti-VE-cadherin
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FIGURE 3. Experiments with glucocorticoid and MR agonists. (A) Expression of corticosteroid target genes (FKBP5, GILZ, PER1, and SGK1) in
CECs in response to the different treatment regimens with cortisol. Error bars represent standard deviation (SD). ***P¼0.0002; ****P < 0.0001. n¼3
donors (ages 77, 68, 93). (B) Dose-response curve of cortisol. Expression of corticosteroid target genes in CECs after treatment with increasing
concentrations of cortisol. PER1 has the largest maximum efficacy (Emax) compared with FKBP5 and GILZ. Error bars represent SD. SGK1, in
contrast to the other genes, did not respond to the treatment. n¼1 donor (age 92). (C) Assessment of the most effective glucocorticoid. Expression
of corticosteroid target genes in response to intermittent treatment with either cortisol or dexamethasone in two different concentrations (and
vehicle as negative control). Comparable results were observed after dexamethasone and after cortisol administration. Error bars represent SD. ***P
¼ 0.0002; ****P < 0.0001. n ¼ 1 donor (age 66). EC50, half maximal effective concentration for gene expression response.
antibody; 1:350 dilution), using Alexa Fluor 647-conjugated goat anti-rabbit IgG secondary antibody. Nuclei were stained with 40,6-diamidino-2-
phenylindole (blue). Staining for VE-cadherin in MACS-isolated CECs (E) is localized at the plasma membrane. 403 original magnification. (G)
Expression of vimentin and CEC-specific markers after two MACS procedures for the CECs and the effluent cultured, which were cultured under the
same conditions. Gene expression of the effluent was normalized to CECs. Paired t-test, *P < 0.05; **P < 0.01. n¼ 1 donor (age 94).
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DISCUSSION
In this study, we established a human CEC culture that is
responsive to corticosteroid hormones. The administration of
cortisol to human CECs in an intermittent rhythm led to the
upregulation of primary corticosteroid target genes, and this
was mediated via the GR. As exogenous corticosteroid
exposure is the single most important risk factor for CSC, we
propose that this system may be used for research into this
common chorioretinopathy. Conversely, corticosteroids are an
important means of treatment for other ocular diseases that
appear to originate in the choroid, such as several forms of
posterior uveitis. We therefore propose that the described
human CEC culture model can also be used for research into
these ocular diseases that involve the choroid and choroidal
endothelium. In contrast with available literature on isolating
and culturing CECs,13,14,22 we separated the RPE and the
choroid by using 0.05% TE at 378C for 1 hour, which was
already sufficient for brushing the RPE from the choroid and
resulted in sufficient CEC culture. Vimentin has been proposed
as a specific fibroblast marker,31 but its expression levels did
not correspond to our gene expression analysis. Therefore, our
study lacks a suitable marker to detect fibroblast contamina-
tion. This would need attention in future studies because the
assessment of the purity of our CEC cultures can only be
interpreted by expression of EC-specific markers, such as VE-
cadherin. Besides the fact that we performed a comprehensive
characterization to confirm the CEC phenotype, we also
describe the first detailed protocol to study the effects of
corticosteroids on CECs.
Interestingly, the administration of cortisol to human CECs
in an intermittent rhythm rather than a continuous adminis-
tration in this study showed a stable response of corticosteroid
target genes in all samples, and this response was mostly
higher than in the continuous cortisol administration. The
strong response of these genes to intermittent cortisol
administration may be explained by the fact that this
intermittent stimulation comes closer to the in vivo situation
with diurnal rhythm in blood cortisol levels as compared with
continuous stimulation. Continuous high cortisol levels may
lead to desensitization of the response due to homologous
downregulation or other mechanisms.32–34
All four tested corticosteroid responsive genes have been
shown to be regulated by both the GR and the MR in several
studies.25,26,28 Although the target genes were not responsive
to aldosterone treatment in our CEC experiments, studies have
demonstrated that these genes are regulated by the MR in other
tissues, such as cortical-collecting duct cells.27,29,35 The mRNA
of FKBP5, PER1, and GILZ showed significant upregulation
after cortisol treatment in our study. The lack of any effect on
SGK1 may be related to its transient induction upon hormone
stimulation.27,36 However, after treatment for 45 minutes, no
SGK1 upregulation was found, which argues for the possibility
that SGK1 is regulated in a tissue-specific manner (Supple-
mentary Fig. S3E). Interestingly, GR-mediated responses to
corticosteroids were evident, but MR-mediated responses
could not be established in these experiments. Dexamethasone
induced a similar effect on the target genes as cortisol, whereas
the MR-specific agonist aldosterone was without effect.
Furthermore, blocking GR activation during cortisol treatment
with the GR antagonist mifepristone demonstrated similar
results as the vehicle treatment, suggesting that the GR is
essential for the induction of corticosteroid target genes in
CECs. On the other hand, the MR antagonist spironolactone,
which is the most potent MR antagonist currently used in
clinical practice, did not attenuate cortisol-induced target gene
expression.37 Of note, we included 5% of cortisol-containing
calf serum in our culture medium, under the assumption that a
model for disease development should compare (normal) low
to moderate exposure to (pathogenic) high exposure, rather
than an all-or-nothing response. The lack of an effect of
continuous MR-antagonist treatment argues against the possi-
bility that low basal cortisol levels may already activate the
high-affinity MR.
Our study results were obtained from a CEC culture model
and cannot be compared directly to in vivo animal and human
studies,12 as our results do contrast with these previous
studies. After all, these studies emphasized the importance of
the MR and the possible role of MR antagonists in CSC. After
intravitreal injection of the glucocorticoid corticosterone in rat
eyes, choroidal enlargement and hyperpermeability have been
observed, resembling abnormalities in CSC.2–5,12 Comparable
results were seen after injection of aldosterone, pointing to a
role for MR activation in CSC. Furthermore, the finding of
CSC(-like) changes in primary hyperaldosteronism indicate a
role for the MR in the pathogenesis of CSC.11 Zhao et al.12 have
proposed an underlying mechanism of this association:
aldosterone could lead to transcriptional upregulation of the
endothelial vasodilatory potassium channel KCa2.3, and
blockade of this channel prevents aldosterone-induced choroi-
dal thickening (pachychoroid),38 which is typical for CSC and
which has led to the introduction of MR antagonists for CSC in
clinical practice. Nonetheless, the variation in the KCa2.3
FIGURE 4. Box plots of corticosteroid target gene expression in CECs
in response to intermittent treatment with 107 M cortisol compared
with vehicle. Each box plot represents the log10 of the normalized (to
LRP10) expression values on the x-axis for each gene of interest on the
y-axis. The closed boxed represent the first to the third quartiles from
left to right, the band inside the box represents the median, and the
whiskers represent the minimum and maximum values. Small circles
represent values more than 1.5 times the interquartile range. **P <
0.00625; ***P < 0.00001. n¼5 donors (ages 77, 68, 93, 80, and 66). AU,
arbitrary units.
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channel was very small at the protein level, suggesting the
involvement of other mechanisms in inducing the observed
choroidal changes in the rat model.12 Moreover, no serous fluid
under the retina was observed during these studies, which is a
typical finding for CSC.12,39 Despite several retrospective
reports on a possible reduction and/or resolution of subretinal
fluid after treatment with the MR antagonists eplerenone and
spironolactone in CSC patients,40–42 the efficacy of these
medications is under debate, and the spontaneous resolution
of subretinal fluid may also occur in CSC.43,44 Large
FIGURE 5. Role of different receptors after corticosteroid administration. (A) Expression of corticosteroid target genes (FKBP5, GILZ, PER1, and
SGK1) in CECs after treatment with aldosterone and/or dexamethasone. Transcriptional upregulation after treatment with dexamethasone was
observed, but aldosterone treatment did not lead to transcriptional upregulation. Error bars represent standard deviation (SD). *P¼ 0.0332; **P¼
0.0021; ***P¼ 0.0002; ****P < 0.0001. n¼ 1 donor (age 78). (B) Expression of corticosteroid target genes in CECs in response to treatment with
either cortisol plus mifepristone (GR antagonist) or cortisol plus spironolactone (MR antagonist). The GR antagonist mifepristone blocked the
transcriptional upregulation of target genes by cortisol, whereas the MR antagonist spironolactone did not. Error bars represent SD. ***P¼0.0002;
****P < 0.0001. n ¼ 1 donor (age 94). (C) Expression of corticosteroid target genes in CECs in response to treatment with either intermittent
cortisol, continuous spironolactone, or intermittent cortisol plus continuous spironolactone. Error bars represent SD. ****P < 0.0001. n¼1 donor
(age 57).
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prospective randomized controlled trials are currently lacking,
but the first randomized controlled trials comparing epler-
enone treatment with either sham (VICI trial, isrctn.com
identifier: ISRCTN92746680) or photodynamic therapy (SPEC-
TRA trial, clinicaltrials.gov identifier: NCT03079141) are
currently being performed. Our study indicates that GR-
mediated effects may play an important role in CECs upon
corticosteroid exposure, and this is in line with the fact that
pure glucocorticoids with minimal MR binding affinity can also
cause CSC.5 Our findings may have implications for CSC
pathogenesis and current treatment practices for CSC, as MR
antagonists are commonly prescribed treatments. Possibly, the
use of GR antagonists, such as mifepristone, may be
appropriate in the treatment of CSC.
The absence of a functional MR in our model does not
directly mean that this receptor is irrelevant in the corticoste-
roid response of CECs or CSC pathophysiology and may
indicate two things. First, and most trivial, the cells may have
lost functional MR protein upon in vitro culture, a phenom-
enon that has been described previously in kidney cells.35 To
gain more insight into this, we have assessed MR expression in
cultured and in directly postmortem-isolated CECs. Expression
of the MR appeared to be variable and consistently lower than
the GR in all tested samples on both the mRNA and protein
level (lower than human embryonic kidney cells, in which no
functional MR response is present) (Supplementary Fig. S4).
Nevertheless, considering none of our samples were from CSC
patients, low MR protein levels or a lack of MR response may
be the reasons not to develop the disease. However, it is
practically impossible to evaluate this in patient material.
Furthermore, in vitro conditions might be such that MR-
mediated responses will not occur, possibly due to lack of
inflammatory factors or specific redox potentials.45,46 On the
other hand, in kidney epithelium cells that have lost their MR
expression over many cell passages, the ability of the GR to
mechanistically take over typical MR-mediated actions has
been described.27 Second, the MR can play a role in CSC
pathogenesis, but this effect may not be on ECs. We have
previously found that a gain-of-function variant of MR was
protective for the disease.10 Although speculative, certain MR
variants have shown to be protective for neuropsychiatric
disorders, such as depression, and might in this way have a
diminishing effect on stress-related cortisol levels and thereby
CSC as well.47 Further histologic studies on postmortem-
isolated choroidal tissue may shed a light on MR expression
and its responsiveness to corticosteroids, closer to the in vivo
situation, to better elucidate the role of the MR in CSC
pathophysiology.
In conclusion, in this study, human CECs were cultured and
characterized, and the effect of administration of corticoste-
roids to these cells was investigated. We show the responsive-
ness of CECs to corticosteroids and the importance of the GR
in this effect. We believe this study design to be an in vitro
model that is very suitable to investigate the role of GR-
mediated effects in the etiology of CSC and other diseases of
the choroid involving CECs. Further studies may be aimed at
RNA sequencing as a more unbiased approach to assess
changes in gene expression in CECs upon triggers such as
cortisol exposure. Other interesting readouts might be focused
on permeability assays, transendothelial resistance, or electron
microscopy, providing additional information on the functional
effects of corticosteroids on CECs. Moreover, this model also
allows for investigations of the role of the complement system
in CECs, which has been related to CSC in genetic studies.39
These and other studies will help to identify as yet unknown
pathways involved in the pathogenesis of CSC and the effect of
corticosteroids on CECs.
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